DNA - NYSE
Ginkgo Bioworks Holdings, Inc.
$8.73
-6.4%Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
At a Glance
Live Snapshotdna
Cash and Short Term Investments
Last Annual Value
422.62M
3-Year CAGR
-32%
5-Year CAGR
2%
10-Year CAGR
-2%
Ginkgo Bioworks Holdings, Inc. Competitors Analysis of Cash and Short Term Investments
| Company | Cash and Short Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Ginkgo Bioworks Holdings, Inc. NYSE:DNA | 422.62M | -23.5% | -22.9% | N/A | |
 Vir Biotechnology, Inc. NASDAQ:VIR | 462.86M | -32.8% | -8.2% | N/A | |
 Replimune Group, Inc. NASDAQ:REPL | 483.80M | -6.0% | 0.3% | N/A | |
 Arvinas, Inc. NASDAQ:ARVN | 685.40M | -18.4% | -14.5% | 34.4% | |
 Iovance Biotherapeutics, Inc. NASDAQ:IOVA | 296.98M | 2.0% | -10.1% | 6.0% | |
 Maravai LifeSciences Holdings, Inc. NASDAQ:MRVI | 216.89M | -27.7% | -17.0% | N/A | |
 Astria Therapeutics, Inc. NASDAQ:ATXS | 328.13M | 10.0% | 21.2% | 23.9% | |
 ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP | 312.82M | 27.7% | 53.0% | N/A | |
 MeiraGTx Holdings plc NASDAQ:MGTX | 65.93M | -20.2% | -13.7% | 14.2% | |
 MBX Biosciences, Inc. Common Stock NASDAQ:MBX | 373.70M | 66.7% | N/A | N/A |
Ginkgo Bioworks Holdings, Inc. Fair Value Envelope
Related Guides
Continue your DNA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.